首页> 美国卫生研究院文献>Hematology Reports >Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient
【2h】

Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient

机译:成功的鞘内化疗联合放疗然后联合波马利度胺和低剂量地塞米松维持疗法治疗原发性浆细胞白血病患者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Primary plasma cell leukemia (PPCL) is a rare aggressive variant of plasma cell disorder and frequently presents with extramedullary disease. Central nervous system (CNS) involvement with PPCL has an extremely poor prognosis. We describe a 46-year-old man with PPCL treated with a combination of lenalidomide, bortezomib, and dexamethasone as induction therapy following upfront allogeneic stem cell transplantation (allo-SCT). Despite achieving a very good partial response, the patient suffered from an isolated CNS relapse 12 months after allo-SCT. He was immediately started on concurrent intrathecal chemotherapy (IT) and cranial irradiation (RT). Subsequently, pomalidomide and low-dose dexamethasone (Pd) were given as maintenance therapy. He has been without CNS recurrence for more than 18 months. Our case suggests that concurrent IT and RT followed by Pd maintenance therapy may be an effective option to control CNS relapse of PPCL after allo-SCT.
机译:原发性浆细胞性白血病(PPCL)是浆细胞性疾病的一种罕见侵略性变体,常伴有髓外疾病。 PPCL累及中枢神经系统(CNS)的预后极差。我们描述了一个46岁的PPCL患者,该患者接受来那度胺,硼替佐米和地塞米松的联合治疗作为前体同种异体干细胞移植(allo-SCT)后的诱导疗法。尽管达到了很好的部分反应,但患者在异基因SCT治疗后12个月出现了孤立的中枢神经系统复发。他立即开始并发鞘内化疗(IT)和颅骨放疗(RT)。随后,给予泊马利度胺和小剂量地塞米松(Pd)作为维持治疗。他已经没有CNS复发18个月了。我们的案例表明,同时进行IT和RT以及Pd维持治疗可能是控制allo-SCT后PPCL中枢神经系统复发的有效选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号